Show simple item record

dc.contributor.authorEyal, Nir
dc.contributor.authorLipsitch, Marc
dc.contributor.authorSmith, Peter G.
dc.date.accessioned2020-03-24T11:07:32Z
dc.date.issued2020-03
dc.identifier.citationEyal, Nir, Marc Lipsitch, and Peter G. Smith. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure (March 2020).en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:42639016*
dc.description.abstractControlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional Phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, they have a high baseline risk of natural infection, and during the trial they receive frequent monitoring and, following any infection, the best available care.en_US
dc.language.isoen_USen_US
dash.licenseLAA
dc.titleHuman Challenge Studies to Accelerate Coronavirus Vaccine Licensureen_US
dc.typeJournal Articleen_US
dc.description.versionAuthor's Originalen_US
dc.date.available2020-03-24T11:07:32Z
dash.affiliation.otherHarvard T.H. Chan School of Public Healthen_US
dash.contributor.affiliatedEyal, Nir
dash.contributor.affiliatedLipsitch, Marc


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record